{"id":"W4405039612","doi":"10.1182/blood-2024-193201","title":"Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Myeloid leukemia; Dasatinib; Medicine; Nilotinib; Tyrosine-kinase inhibitor; Bosutinib; Internal medicine; Imatinib; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322636,0.0002474293,0.0003861797,0.001588994,0.0006394516,0.001105393,0.0003398606,0.0003953748,0.002007536],"category_scores_gemma":[0.003435378,0.0002667845,0.0004841667,0.002459171,0.0003809687,0.0006746575,0.0005130439,0.0004191743,0.0003008451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00162866,"about_ca_system_score_gemma":0.001859864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02016046,"about_ca_topic_score_gemma":0.02955661,"domain_scores_codex":[0.9984053,0.0004984414,0.0002013728,0.0004237432,0.0003384966,0.0001327199],"domain_scores_gemma":[0.9931226,0.000906147,0.004293082,0.0002351204,0.0009171843,0.0005258598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00120208,0.0002482193,0.9865833,0.0002117566,0.0002031185,0.0002631154,0.0004068404,0.00009055035,0.0003939628,0.00007144757,0.002553931,0.007771743],"study_design_scores_gemma":[0.0003076532,0.0008876235,0.9922615,0.0001428131,0.000209087,0.0007072724,0.0007703294,0.0003192866,0.000376422,0.00002622102,0.003965398,0.00002643819],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.9891671,0.002232864,0.0001847575,0.000244477,0.00001954797,0.0003307556,0.006227541,0.0000242335,0.001568705],"genre_scores_gemma":[0.9928153,0.001103596,0.0003464183,0.0002509467,0.00003125933,0.0001896123,0.004847351,0.000007241025,0.0004083464],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02016046,"threshold_uncertainty_score":0.04008621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02612244091942368,"score_gpt":0.3162155870755888,"score_spread":0.2900931461561652,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}